Verrica Pharmaceuticals Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $35.6M | $7.6M | $5.1M | $9.0M | $12.0M | — | — |
| Cost of Revenue | — | — | $2.6M | $500.0K | — | — | — | — |
| Gross Profit | — | — | $5.0M | $4.6M | — | — | — | — |
| Gross Margin | — | — | 65.6% | 90.2% | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $8.9M | $11.8M | $20.3M | $12.2M | $15.9M | $15.7M | $15.4M |
| SG&A Expense | — | $35.2M | $58.8M | $47.3M | $17.4M | $27.0M | $24.5M | $14.6M |
| Operating Income | — | $-12.2M | $-65.9M | $-65.8M | $-21.3M | $-30.9M | $-40.2M | $-30.1M |
| Operating Margin | — | -34.2% | -871.3% | -1,283.4% | -235.8% | -257.6% | — | — |
| Interest Expense | — | — | — | $4.0M | $2.2M | $4.3M | $3.0M | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | $0 | $0 | $0 | $0 | — | — | — |
| Net Income | — | $-17.9M | $-76.6M | $-67.0M | $-24.5M | $-35.1M | $-42.7M | $-28.2M |
| Net Margin | — | -50.3% | -1,012.1% | -1,307.5% | -271.1% | -292.3% | — | — |
| EPS (Basic) | — | $-1.68 | $-7.39 | $-0.74 | $-0.36 | $-0.65 | $-0.86 | $-0.57 |
| EPS (Diluted) | — | $-1.68 | $-7.39 | $-0.74 | $-0.36 | $-0.65 | $-0.86 | $-0.57 |
| Shares Outstanding (Basic) | 17.2M | 10.7M | 10.4M | 90.7M | 68.3M | 54.1M | 50.9M | 51.6M |
| Shares Outstanding (Diluted) | 17.2M | 10.7M | 10.4M | 90.7M | 68.3M | 54.1M | 50.9M | 51.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |